Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
22 Apr 24
8-K
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
18 Apr 24
ARS
2023 FY
Annual report to shareholders
15 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
8-K
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
20 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
7 Mar 24
8-K
Regulation FD Disclosure
4 Jan 24
8-K
Other Events
15 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
7 Nov 23
8-K
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
7 Nov 23
8-K
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
26 Sep 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
9 Aug 23
8-K
Lumos Pharma Announces Departure of Chief Medical Officer
28 Jun 23
8-K
Lumos to Highlight New LUM-201 Data and Analysis Presented
21 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
15 May 23
8-K
Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at
8 May 23
10-Q
2023 Q1
Quarterly report
5 May 23
8-K
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
3 May 23
ARS
2022 FY
Annual report to shareholders
3 Apr 23
DEFA14A
Additional proxy soliciting materials
31 Mar 23
DEF 14A
Definitive proxy
31 Mar 23
10-K
2022 FY
Annual report
7 Mar 23
8-K
Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology
7 Mar 23
8-K
Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates
1 Mar 23
8-K
Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD
28 Feb 23
8-K
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
12 Dec 22
8-K
Other Events
30 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
14 Nov 22
8-K
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
14 Nov 22
424B5
Prospectus supplement for primary offering
29 Aug 22
EFFECT
Notice of effectiveness
29 Aug 22
CORRESP
Correspondence with SEC
24 Aug 22
UPLOAD
Letter from SEC
23 Aug 22
S-3
Shelf registration
18 Aug 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
Latest ownership filings
4
BRADLEY J POWERS
3 Apr 24
4
Lori D Lawley
3 Apr 24
4
Pisit Duke Pitukcheewanont
3 Apr 24
4
John C. McKew
3 Apr 24
4
Richard J Hawkins
3 Apr 24
4
Aaron Schuchart
3 Apr 24
SC 13G/A
GOLDMAN SACHS GROUP INC
9 Feb 24
4
John C. McKew
7 Feb 24
144
Notice of proposed sale of securities
6 Feb 24
SC 13G
WELLS FARGO & COMPANY/MN
6 Feb 24
4
John C. McKew
5 Feb 24
4
Richard J Hawkins
5 Feb 24
4
Lori D Lawley
5 Feb 24
4
Aaron Schuchart
5 Feb 24
4
BRADLEY J POWERS
5 Feb 24
3
Pisit Duke Pitukcheewanont
10 Jan 24
SC 13D/A
Blackstone Holdings II L.P.
29 Nov 23
4
John C. McKew
3 Aug 23
4
Lori D Lawley
3 Aug 23
144
Notice of proposed sale of securities
2 Aug 23
SC 13D/A
Farb Daniel Stuart
20 Jun 23
SC 13D/A
Farb Daniel Stuart
2 Jun 23
SC 13D/A
Farb Daniel Stuart
25 May 23
4
Lota S. Zoth
12 May 23
4
Es-Johansson An van
12 May 23
4
Thomas A. Raffin
12 May 23
4
Joseph S McCracken
12 May 23
4
KEVIN M. LALANDE
12 May 23
4
CHAD ALLEN JOHNSON
12 May 23
4
BRADLEY J POWERS
4 Apr 23
4
John C. McKew
4 Apr 23
4
Lori D Lawley
4 Apr 23
4
Richard J Hawkins
4 Apr 23
SC 13D
Farb Daniel Stuart
15 Feb 23
SC 13G
GOLDMAN SACHS GROUP INC
7 Feb 23
4
Aaron Schuchart
3 Feb 23
4
BRADLEY J POWERS
3 Feb 23
4
John C. McKew
3 Feb 23
4
Lori D Lawley
3 Feb 23
4
David B Karpf
3 Feb 23